<SEC-DOCUMENT>0001193125-26-298525.txt : 20260708
<SEC-HEADER>0001193125-26-298525.hdr.sgml : 20260708
<ACCEPTANCE-DATETIME>20260708160518
ACCESSION NUMBER:		0001193125-26-298525
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260708
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260708
DATE AS OF CHANGE:		20260708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37465
		FILM NUMBER:		261162443

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d100733d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mcrb="http://serestherapeutics.com/20260708" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-434">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-07-08_to_2026-07-08">0001609809</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mcrb-20260708.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-07-08_to_2026-07-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001609809</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-07-08</xbrli:startDate> <xbrli:endDate>2026-07-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-445">8-K</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt:datemonthdayyearen" id="ixv-446">July 8, 2026</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-447">SERES THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:stateprovnameen" id="ixv-448">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-449">001-37465</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-450">27-4326290</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-451">101 Cambridgepark Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-452">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-453">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-454">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-455">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-456">945-9626</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:boolballotbox" id="ixv-457">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:boolballotbox" id="ixv-458">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:boolballotbox" id="ixv-459">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:boolballotbox" id="ixv-460">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-461">Common stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-462">MCRB</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:exchnameen" id="ixv-463">The Nasdaq Stock Market LLC</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Nasdaq Global Select Market)</p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-07-08_to_2026-07-08" format="ixt-sec:boolballotbox" id="ixv-464">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.02.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reported below under Item 5.07 of this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;Current Report&#8221;), on July&#160;8, 2026, Seres Therapeutics, Inc. (the &#8220;Company&#8221;) reconvened its 2026 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;), which had been adjourned from June&#160;9, 2026 due to a lack of quorum. At the Annual Meeting, the Company&#8217;s stockholders approved an amendment and restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan (the &#8220;2025 Plan&#8221;) to increase the number of shares of the Company&#8217;s common stock available for issuance under the 2025 Plan by 900,000 shares. The amendment and restatement of the 2025 Plan was approved by the Company&#8217;s Board of Directors on April&#160;22, 2026, subject to and effective upon stockholder approval of the amendment and restatement of the 2025 Plan at the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the 2025 Plan, as amended and restated, are described in the section entitled &#8220;Proposal 4 &#8212; Approval of the Amendment and Restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April&#160;27, 2026 (the &#8220;Definitive Proxy Statement&#8221;). The foregoing description of the 2025 Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the 2025 Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.07.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Submission of Matters to a Vote of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;8, 2026, at the Annual Meeting, a total of 4,985,176 shares of the Company&#8217;s common stock were represented in person or by proxy at the meeting, representing approximately 51.75% of the Company&#8217;s outstanding Common Stock as of the April&#160;13, 2026 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company&#8217;s Definitive Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item 1 - Election of three Class&#160;II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:59%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap">NOMINEE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">Votes FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">Votes&#160;WITHHELD</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Berenson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">3,690,033</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">426,428</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">868,715</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claire M. Fraser, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">3,825,690</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">290,771</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">868,715</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard N. Kender</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">3,824,452</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">292,009</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">868,715</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:21%"/>
<td/>

<td style="vertical-align:bottom;width:21%"/>
<td/>

<td style="vertical-align:bottom;width:21%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;ABSTAINED</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center">4,542,915</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">267,601</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">174,660</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">0</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item&#8201;3 - Approval, on an advisory <span style="white-space:nowrap">(non-binding)</span> basis, of the compensation of the Company&#8217;s named executive officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:25%"/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;ABSTAINED</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center">3,374,813</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">620,353</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">121,295</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">868,715</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item 4 - Approval of an amendment and restatement of the Seres Therapeutics, Inc. 2025 Plan to increase the number of shares available for issuance under the plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;ABSTAINED</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center">3,438,763</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">597,484</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">80,214</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">868,715</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Proposal 4. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/>

<td style="vertical-align:bottom;width:19%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">Votes&#160;ABSTAINED</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center">3,299,526</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">741,254</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">75,681</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">868,715</td></tr>
</table> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 5 were approved. Although Item 5 was approved, an adjournment of the Annual Meeting was not necessary because the Company&#8217;s stockholders approved Proposal 4. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d100733dex101.htm">Seres Therapeutics, Inc. 2025 Incentive Award Plan (as amended and restated).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">SERES THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: July&#160;8, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. DesRosier</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Thomas J. DesRosier</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d100733dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ERES</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 I<SMALL>NCENTIVE</SMALL> A<SMALL>WARD</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(<SMALL>AS</SMALL> <SMALL>AMENDED</SMALL> <SMALL>AND</SMALL> <SMALL>RESTATED</SMALL> <SMALL>EFFECTIVE</SMALL> July&nbsp;8, 2026) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>I.<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>URPOSE</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make)
important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Section XI. This Plan constitutes an amendment and restatement of the Seres Therapeutics,
Inc. 2025 Incentive Award Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">III.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL> <SMALL>AND</SMALL> D<SMALL>ELEGATION</SMALL></B><SMALL></SMALL>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration</U><I>.</I> The Plan is administered by the Administrator. The Administrator has authority to
determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under
the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile
inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons
having or claiming any interest in the Plan or any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Appointment of Committees</U><I>.</I> To the extent Applicable Laws
permit, the Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself
any previously delegated authority at any time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">IV.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>TOCK</SMALL> A<SMALL>VAILABLE</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL></B><SMALL></SMALL>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Shares</U><I>. </I>Subject to adjustment under Section VIII and the terms of this Section IV, Awards
may be made under the Plan covering up to the Overall Share Limit. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Share Recycling</U>. If all or any part of an Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased,
canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the
Participant for such Shares or not issuing any Shares covered by the Award, the unused Shares covered by the Award will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in
conjunction with any outstanding Awards shall not count against the Overall Share Limit. Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Overall Share Limit and shall not be available for
future grants of Awards: (i)&nbsp;Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding
obligation (including Shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation); (ii) Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of
the Stock Appreciation Right; and (iii)&nbsp;Shares purchased on the open market with the cash proceeds from the exercise of Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Incentive Stock Option Limitations</U>. Notwithstanding anything to the contrary herein, no more than 3,130,243 Shares may be issued pursuant to the exercise of Incentive Stock Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Substitute Awards</U>. In connection with an entity&#8217;s merger or consolidation
with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such
entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares
subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided in Section IV(b) above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of
Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares
available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to
the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to
the Shares available for Awards under the Plan as provided in Section IV(b) above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors immediately prior to such acquisition or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</U><I>. </I>Notwithstanding any provision to the contrary in
the Plan, the Administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms,
conditions and amounts of all such <FONT STYLE="white-space:nowrap">non-employee</FONT> Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations
as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards
Codification Topic 718, or any successor thereto) of Awards granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director during any fiscal
year of the Company may not exceed $750,000, increased to $1,000,000 in the first year an individual becomes a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director. The Administrator may make exceptions to this limit for individual <FONT
STYLE="white-space:nowrap">non-employee</FONT> Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> Director receiving such additional
compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> Directors. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">V.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTIONS</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U><I>. </I>The Administrator may
grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including Section IX(i) with respect to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and
Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the
Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair
Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or
that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U><I>. </I>The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and
specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Duration of Options</U><I>. </I>Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award
Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise</U><I>. </I>Options and Stock Appreciation Rights may be exercised by
delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full
(i)&nbsp;as specified in Section V(e) for the number of Shares for which the Award is exercised and (ii)&nbsp;as specified in Section IX(e) for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation
Right may not be exercised for a fraction of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Payment Upon Exercise</U><I>. </I>The exercise price of an Option must be
paid in cash, wire transfer of immediately available funds or by check payable to the order of the Company or, subject to Section X(h), any Company insider trading policy (including blackout periods) and Applicable Laws, by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if there is a public market for Shares at the time of exercise, unless the Administrator otherwise determines, (A)&nbsp;delivery
(including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B)&nbsp;the
Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such
amount is paid to the Company at such time as may be required by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to the extent permitted by the Administrator,
delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to the
extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is
good and valuable consideration; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any combination of the above permitted payment forms (including cash, wire transfer or check).
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">VI.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL>; R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL>
U<SMALL>NITS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U><I>.</I> The Administrator may grant Restricted Stock, or the
right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such
shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to
Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award
Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>Dividends</I>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to
such shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of
Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid.
Notwithstanding anything to the contrary herein, with respect to any award of Restricted Stock, dividends which are paid to holders of Common Stock prior to vesting shall not be paid to the Participant holding such Restricted Stock unless and until
the vesting conditions applicable to such award of Restricted Stock are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I>Stock Certificates.</I> The Company may
require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Restricted Stock Units</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>Settlement.</I> The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably
practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I>Stockholder Rights.</I> A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock
Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <I>Dividend Equivalents.</I> If the
Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares
and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.
Notwithstanding anything to the contrary herein, Dividend Equivalents with respect to an Award shall not be paid to the Participant holding such Award unless and until the vesting conditions applicable to the underlying Award are satisfied. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">VII.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>O<SMALL>THER</SMALL> S<SMALL>TOCK</SMALL> <SMALL>OR</SMALL> C<SMALL>ASH</SMALL> B<SMALL>ASED</SMALL>
A<SMALL>WARDS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Other Stock or Cash Based Awards may be granted to Participants, including
Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any
conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is
otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock
or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. If the Administrator
provides, a grant of an Other Stock or Cash Based Award may provide a Participant with the right to receive Dividend Equivalents; provided that, Dividend Equivalents with respect to an Other Stock or Cash Based Award shall not be paid to the
Participant holding such Other Stock or Cash Based Award unless and until the vesting conditions applicable to the underlying Other Stock or Cash Based Award are satisfied. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">VIII.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>FOR</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL>
S<SMALL>TOCK</SMALL> <SMALL>AND</SMALL> C<SMALL>ERTAIN</SMALL> O<SMALL>THER</SMALL> E<SMALL>VENTS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Equity Restructuring</U><I>.</I> In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Section
VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the
Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section VIII(a) will be nondiscretionary and final and binding on the
affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Corporate
Transactions</U><I>.</I> In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, repurchase, recapitalization,
liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or
other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any
Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give
effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#8217;s request, is hereby authorized to take any one or more of the
following actions whenever the Administrator determines that such action is appropriate in order to (x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with
respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or event or (z)&nbsp;give effect to such changes in Applicable Laws or accounting principles: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To provide for the cancellation of any such Award in exchange for either an amount of
cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as
applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award
may be terminated without payment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) To provide that such Award shall vest and, to the extent applicable, be exercisable as to all
shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To provide that such
Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate
adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards
and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Section IV hereof on the maximum number and kind of shares which may be issued) and/or in the terms and conditions of
(including the grant or exercise price), and the criteria included in, outstanding Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) To replace such Award with other rights
or property selected by the Administrator; and/or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) To provide that the Award will terminate and cannot vest, be exercised or become
payable after the applicable event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Administrative Stand Still</U><I>.</I> In the event of any pending stock dividend, stock
split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of
Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>General</U><I>.</I> Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no
Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or
other corporation. Except as expressly provided with respect to an Equity Restructuring under Section VIII(a) above or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into
Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will
not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii)&nbsp;any merger,
consolidation dissolution or liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for
Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Section VIII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Change in
Control</U><I>.</I> Notwithstanding Section VIII(b) above, if a Change in Control occurs and Awards are not continued, converted, assumed, or replaced with a comparable award (as determined by the Administrator) by (i)&nbsp;the Company or
(ii)&nbsp;a successor entity or its parent or subsidiary (an &#8220;<B><I>Assumption</I></B>&#8221;), and provided that the Participant has not had a Termination of Service, then immediately prior to the Change in Control, such Awards (other than
any Award that is regularly scheduled to vest based on the attainment of Performance Criteria or other performance-based vesting conditions) will become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and
other restrictions on such Awards will lapse, in which case, such Awards will be canceled upon the consummation of the Change in Control in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange for the right to receive the Change in Control consideration payable to other holders of Shares, which may be on such terms and conditions as apply generally to holders of Shares under
the Change in Control documents (including, without limitation, any escrow, <FONT STYLE="white-space:nowrap">earn-out</FONT> or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and
determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute &#8220;nonqualified deferred compensation&#8221; that may not be paid upon the
Change in Control under Section&nbsp;409A without the imposition of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable
under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such
Award may be terminated without payment. An Award will be considered replaced with a comparable award if the Award is exchanged for an amount of cash or other property with a value equal to the amount that could have been obtained upon the
settlement of such Award in such Change in Control (as determined by the Administrator), even if such cash or other property payable with respect to the unvested portion of such Award remains subject to similar vesting provisions following such
Change in Control. Notwithstanding the foregoing, the Administrator will have full and final authority to determine whether an Assumption of an Award has occurred in connection with a Change in Control. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">IX.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL> A<SMALL>PPLICABLE</SMALL> <SMALL>TO</SMALL>
A<SMALL>WARDS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U><I>.</I> Except as the Administrator may determine or
provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of
descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent
relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Documentation</U><I>.</I> Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator
determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Discretion</U><I>.</I> Except
as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions
thereof) uniformly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Status</U><I>.</I> The Administrator will determine how the disability, death, retirement,
authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal
representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<U>Withholding</U><I>.</I> Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#8217;s Awards by the date of the
event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the minimum statutory withholding rates from any payment of any kind otherwise due to a Participant. Participants may satisfy such
tax obligations in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, or subject to Section X(h) and any Company insider trading policy (including blackout periods), (i) to the extent permitted
by the Administrator, in whole or in part by delivery of Shares, including Shares retained from the Award creating the tax obligation, valued at their Fair Market Value, (ii)&nbsp;if there is a public market for Shares at the time the tax
obligations are satisfied, unless the Administrator otherwise determines, (A)&nbsp;delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to
deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly
to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iii)&nbsp;any combination of the foregoing permitted payment forms
(including cash, wire transfer or check). If any tax withholding obligation will be satisfied under clause (i)&nbsp;of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately preceding sentence by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is
satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to
the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the
transactions described in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendment of Award; No Repricing</U><I>.</I> The Administrator may amend, modify or
terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT>
Stock Option. The Participant&#8217;s consent to such action will be required unless (i)&nbsp;the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or
(ii)&nbsp;the change is permitted under Section VIII or pursuant to Section X(f). Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may not, except pursuant to Section VIII, without the approval of the
stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation
Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Conditions on Delivery of Stock</U><I>. </I>The Company will not be obligated to deliver any Shares under the Plan or remove
restrictions from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii)&nbsp;as determined by the Company, all other legal matters regarding the issuance and
delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or
agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the
lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Acceleration</U><I>. </I>The Administrator may at any time provide that any Award will become immediately vested and fully or partially
exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Additional Terms of
Incentive Stock Options</U><I>. </I>The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections 424(e) or (f)&nbsp;of the Code,
respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of
the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section&nbsp;422 of the Code. By accepting an Incentive
Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&nbsp;two years from the grant date
of the Option or (ii)&nbsp;one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other
consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221;
under Section&nbsp;422 of the Code . Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section&nbsp;422 of the Code for any reason, including becoming exercisable with respect to
Shares having a fair market value exceeding the $100,000 limitation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> will be a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">X.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Right to Employment or Other Status</U><I>. </I>No person will have any claim or right to be granted an Award, and the grant of an
Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a
Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Rights as Stockholder; Certificates</U><I>. </I>Subject to the Award Agreement, no
Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the
Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of
the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Effective Date and Term of Plan</U><I>. </I>The Plan, as amended and restated, shall become effective as of the Amendment Date. The
Plan will remain in effect until March&nbsp;3, 2035. No Awards may be granted under the Plan during any suspension period or after Plan termination. Notwithstanding anything in the Plan to the contrary, an Incentive Stock Option may not be granted
under the Plan after ten years from the earlier of (i)&nbsp;the date the Board adopted the Plan or (ii)&nbsp;the date the Company&#8217;s stockholders approved the Plan, but Awards previously granted may extend beyond that date in accordance with
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment of Plan</U><I>. </I>The Administrator may amend, suspend or terminate the Plan at any time; provided that no
amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. Awards outstanding at the time of any Plan
suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with
Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Provisions for Foreign Participants</U><I>.</I> The Administrator may modify Awards granted to Participants who
are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency,
employee benefit or other matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Section</U><U></U><U>&nbsp;409A</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>General.</I> The Company intends that all Awards be structured to comply with, or be exempt from, Section&nbsp;409A, such that no
adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards,
adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to
(A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date.
The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&nbsp;409A or otherwise. The Company will have no obligation under this Section X(f) or otherwise to avoid the taxes, penalties or interest under
Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred
compensation&#8221; subject to taxes, penalties or interest under Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I>Separation from Service.</I> If an Award
constitutes &#8220;nonqualified deferred compensation&#8221; under Section&nbsp;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes
under Section&nbsp;409A, be made only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&nbsp;409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the
Participant&#8217;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a
&#8220;separation from service.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <I>Payments to Specified Employees.</I> Notwithstanding any contrary provision in the Plan
or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&nbsp;409A and as the Administrator determines) due to his
or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">six-month</FONT> period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified employee&#8217;s death) and will
instead be paid (as set forth in the Award Agreement) on the day immediately following such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively practicable thereafter (without interest). Any payments of
&#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Limitations on Liability</U><I>.</I> Notwithstanding any other provisions of the Plan and to the fullest extent permitted by the
General Corporation Law of the State of Delaware and the Company&#8217;s certificate of incorporation and bylaws, (a)&nbsp;no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any
Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan
because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary, and (b)&nbsp;the Company will indemnify and hold harmless each director,
officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217;
fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U><I>.</I> The Company may, at the request of any underwriter representative or
otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period
of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Data Privacy</U>. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use
and transfer, in electronic or other form, of personal data as described in this paragraph by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in
the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number; birthdate; social security, insurance number or other
identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;<B><I>Data</I></B>&#8221;). The
Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer
the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data
privacy laws and protections than the recipients&#8217; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and
manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held
only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about
the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section X(i) in writing, without cost, by contacting the local
human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws
the consents in this Section X(i). For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Severability</U><I>.</I> If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the
illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Governing Documents</U><I>. </I>If any contradiction occurs between the Plan and any
Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a
specific provision of the Plan will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Governing Law</U>. The Plan and all Awards will be governed by and interpreted in
accordance with the laws of the State of Delaware, disregarding any state&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles requiring the application of a jurisdiction&#8217;s laws other
than the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Claw-back Provisions</U>. All Awards (including any proceeds, gains or other economic benefit the
Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to the Company&#8217;s Policy for Recovery of Erroneously Awarded Compensation,
adopted effective as of October&nbsp;2, 2023, as may be amended from time to time, and any other clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <U>Titles and Headings</U>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the
Plan&#8217;s text, rather than such titles or headings, will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <U>Conformity to Securities Laws</U>. Participant acknowledges
that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws
permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <U>Relationship to Other
Benefits</U>. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as
expressly provided in writing in such other plan or an agreement thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) <U>Broker-Assisted Sales</U><I>.</I> In the event of a
broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section IX(e): (a) any Shares to be sold through the
broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an
average price; (c)&nbsp;the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs,
damages, or expenses relating to any such sale; (d)&nbsp;to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as
reasonably practicable; (e)&nbsp;the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s
applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">XI.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL></B><SMALL></SMALL> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following words and phrases will have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<B><I>Administrator</I></B>&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the
Plan have been delegated to such Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<B><I>Amendment Date</I></B>&#8221; means the date on which this Plan, as amended
and restated, is approved by the Company&#8217;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<B><I>Applicable Laws</I></B>&#8221; means the requirements
relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is
listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
&#8220;<B><I>Award</I></B>&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#8220;<B><I>Award Agreement</I></B>&#8221; means a written agreement evidencing an
Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#8220;<B><I>Board</I></B>&#8221; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#8220;<B><I>Change in Control</I></B>&#8221; means and includes each of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement
filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (A)&nbsp;and (B)&nbsp;of subsection (iii)&nbsp;below) whereby any &#8220;person&#8221; or related &#8220;group&#8221;
of &#8220;persons&#8221; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a
&#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new
Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (i)&nbsp;or (iii)) whose election by the Board or nomination for election by the
Company&#8217;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at the beginning of the
<FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)
which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a
result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#8220;<B><I>Successor Entity</I></B>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power
of the Successor Entity; <U>provided</U>,<I> </I><U>however</U>, that no person or group shall be treated for purposes of this clause (B)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result
of the voting power held in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change in Control constitutes a
payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under Section&nbsp;409A, the
transaction or event described in subsection (i), (ii) or (iii)&nbsp;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a
&#8220;change in control event,&#8221; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control
and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#8220;<B><I>Code</I></B>&#8221; means the Internal Revenue Code of 1986, as amended,
and the regulations issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#8220;<B><I>Committee</I></B>&#8221; means one or more committees or subcommittees of the
Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> it is intended that each
member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> director&#8221;
within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#8217;s failure to qualify as a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT> director&#8221; within the meaning of Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#8220;<B><I>Common Stock</I></B>&#8221; means the common stock of the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#8220;<B><I>Company</I></B>&#8221; means Seres Therapeutics, Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#8220;<B><I>Consultant</I></B>&#8221;<I> </I>means any person, including any adviser, engaged by the Company or its parent or Subsidiary
to render services to such entity if the consultant or adviser: (i)&nbsp;renders <I>bona fide</I> services to the Company; (ii)&nbsp;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does
not directly or indirectly promote or maintain a market for the Company&#8217;s securities; and (iii)&nbsp;is a natural person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)
&#8220;<B><I>Designated Beneficiary</I></B>&#8221;<I> </I>means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the
Participant dies or becomes incapacitated. Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#8220;<B><I>Director</I></B>&#8221; means a Board member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#8220;<B><I>Disability</I></B>&#8221; means a permanent and total disability under Section&nbsp;22(e)(3) of the Code, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#8220;<B><I>Dividend Equivalents</I></B>&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in
cash or Shares) of dividends paid on Shares. No Dividend Equivalents shall be payable on Options or Stock Appreciation Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)
&#8220;<B><I>Employee</I></B>&#8221; means any employee of the Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#8220;<B><I>Equity
Restructuring</I></B>&#8221; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a large, nonrecurring cash
dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#8220;<B><I>Exchange Act</I></B>&#8221; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#8220;<B><I>Fair Market Value</I></B>&#8221; means, as of any date, the value of Common Stock determined as follows: (i)&nbsp;if the
Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date
during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; (ii)&nbsp;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation
system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems
reliable; or (iii)&nbsp;without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) &#8220;<B><I>Greater Than 10% Stockholder</I></B>&#8221; means an individual then owning (within the meaning of Section&nbsp;424(d) of the
Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&nbsp;424(e) and (f)&nbsp;of the Code, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &#8220;<B><I>Incentive Stock Option</I></B>&#8221; means an Option intended to qualify
as an &#8220;incentive stock option&#8221; as defined in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w)
&#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</I></B>&#8221;<I> </I>means an Option not intended or not qualifying as an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#8220;<B><I>Option</I></B>&#8221; means an option to purchase Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) &#8220;<B><I>Other Stock or Cash Based Awards</I></B>&#8221; means cash awards, awards of Shares, and other awards valued wholly or
partially by referring to, or are otherwise based on, Shares or other property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) &#8220;<B><I>Overall Share Limit</I></B>&#8221; means
3,130,243 Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) &#8220;<B><I>Participant</I></B>&#8221; means a Service Provider who has been granted an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) &#8220;<B><I>Performance Criteria</I></B>&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to
establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and <FONT STYLE="white-space:nowrap">non-cash</FONT>
equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net
operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and
free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control
measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance;
implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate
financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions;
financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing
activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease, peer group results, or market performance indicators or indices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) &#8220;<B><I>Plan</I></B>&#8221; means this 2025 Incentive Award Plan, as amended or restated from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) &#8220;<B><I>Restricted Stock</I></B>&#8221; means Shares awarded to a Participant under Section VI subject to certain vesting conditions
and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) &#8220;<B><I>Restricted Stock Unit</I></B>&#8221; means an unfunded, unsecured right to receive, on the
applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) &#8220;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#8221; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#8221; means
Section&nbsp;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh)
&#8220;<B><I>Securities Act</I></B>&#8221; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) &#8220;<B><I>Service
Provider</I></B>&#8221; means an Employee, Consultant or Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) &#8220;<B><I>Shares</I></B>&#8221;<I> </I>means shares of Common
Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) &#8220;<B><I>Stock Appreciation Right</I></B>&#8221; means a stock appreciation right
granted under Section V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) &#8220;<B><I>Subsidiary</I></B>&#8221; means any entity (other than the Company), whether domestic or
foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of
the total combined voting power of all classes of securities or interests in one of the other entities in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm)
&#8220;<B><I>Substitute Awards</I></B>&#8221; shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case
by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn)
&#8220;<B><I>Termination of Service</I></B>&#8221; means the date the Participant ceases to be a Service Provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mcrb-20260708.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 7/8/2026 10:42:34 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:mcrb="http://serestherapeutics.com/20260708"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://serestherapeutics.com/20260708"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260708_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260708_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mcrb-20260708_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 7/8/2026 10:42:34 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mcrb-20260708_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 7/8/2026 10:42:34 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mcrb-20260708.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001609809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  08,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SERES THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-4326290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">945-9626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCRB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d100733d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d100733d8k.htm">d100733d8k.htm</File>
    <File>mcrb-20260708.xsd</File>
    <File>mcrb-20260708_lab.xml</File>
    <File>mcrb-20260708_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d100733d8k.htm": {
   "nsprefix": "mcrb",
   "nsuri": "http://serestherapeutics.com/20260708",
   "dts": {
    "inline": {
     "local": [
      "d100733d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mcrb-20260708.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mcrb-20260708_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mcrb-20260708_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-07-08_to_2026-07-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d100733d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-07-08_to_2026-07-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d100733d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serestherapeutics.com//20260708/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-26-298525-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-298525-xbrl.zip
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M &P7+I4'BY8TQC>A&HU"J!K1WP.%CO?,1'HORO!%&X3-'H1&!M :.Z"YT/G
MSUYH=7#<6H)D:,6@/CQIP[Z*MHXS55Z:4 NV;GYXJ]7VX0V\=O0-DIF)>/RA
M9( V[C\&)&ZWB1W[19B*S23Z.S"S3J3/:VM<Z[2F9]R$XR*0\D+/28TMBRF%
MO0\IO&O'VL;K@**5)VP<&Y[GE+NYYXW_W2C_+7;^3TZ"O?^396=#:[CO?K+Q
M_GTYWK\_;*NW.".V<ML_==&YN6YW6JTMMYM>?;0/S8DBGV^Z;P(XZ.6/]MW7
MKZVKRT.CL':=X),4WY@,X'2$F]$X+QQY"X5AIQO%9WV(R^^E@. S$ZY1@C:"
ML&[M#O+VKDMR(1*3#' )-:F_,]''[;*H?.8-06,VLN03NK\JN&!AKW.\63I-
M(5VN0>Q>*+P#7(K@(17-ZCO I%JNIBM&Z4VS']X+[X*7 9X%N<Z2SY(J/"MZ
M.\Q>9M\-_U;-$O+P.\#%!$FJ5(QW@,D!^/?'5\I=" AP?:F3);_IM.IWQ-+%
M=+%DO@-<S)J9SN-5\6^.R0)+GSP?U.\Q&C,A&NO2Q-4XT>KQ[.;3K>06>\33
M4T,Q5JPI!(;DY.KJ%L/D97$G8N4QC=ILMG7?X59R!W[ Y2B.C0=< 4T)WMA*
M6!"37S*+X:)_,!$%(XB_?^BH;,MT[.>",K.X75!F&B^*KW;1[%W%96\7,FV!
M2]!QXTNCW>G=O3.D/O7N *W6?F.[S=#Z^X5[JT/;8KI4--.UT'@<,*8VRY5T
M.;]?AW )6*-23)?+^_6(EX#-OP/;'&YY%,!"1[N2.F,!-VSM!ZXPZV,MZY_B
MSZ'UN3:E\6FN/E5<I2-3;T5I) GS/V_-,:_1)BR^O4C,9)4<S;!9VLX,&[47
MV=-=-#N:X:,9/IKA5YKA0KH AJEJ['>I<0G@LIE/%TH'!VN81MJL'=SI>$>!
M<C%AAM%*OCX=3J?!K$UP6YN\YD$W1S,<FN'RT0P?S?#1#/]SS'"Q !:B?'![
M6*I5TL5J\>#V,)\VC<-#?3]6N+3$"@<I\4F[.Y\VQ0?$99CS0^4DK5.*@BO!
M"%HS#'OQ1C!,& .(P9DTR8+T*DQ056,,=CGV_Z!U8IB<Y?/@\/LB1)W0%^2
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M':^^HJLN-_Q[3]^>0CL]>TWP1B6YA>'!=( PT^#PX"7U*=&_YWF*6:FV'1[
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MVE%?$,!RQ 75^7C4*F_.40UN2'D$:W-!*W\Z<3O96*V# 2W445IR6HD0CMZ
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MLE1)6AW"-LMKWOP2MN#M^?6#OQ]]O)KXD:*53RH)9_(T'@6BDT:+4E>JFFU
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M[^#U#=Y90M+0&(KI2LY[..M6_CSUO'&DIC>7Q67M=5;5^]')W\@)UWK27!K
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M;441V"F+CO"4:7(ZS.=YY$L=5&2MX"#U.'=^A"$/ZR"=6NCFYV"^BG!2:K3
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MIQ@8<J /+&K,H\,WC(1&L=H]A7$:%PXF_QH5SE:S?#RZ*"![;]R2D@[Z_(9
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M:J[W%"AI.MPCR%EZ]AAV=B<)G9'P/':JZS B[MHP/@_F\%L T0XZU$3KZ9A
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MQ$^!CSB<3N*B-O1CKGCAK,/XJI(7U@2H(>(V2\2"*/P,E" 4/6"AU4*EZUM
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M.HKT@$KN'$Y<YNOV>AJ>N6",K^R*LC68$8KE$E=V"IV_N(@=CF%-VEM%DGT
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MM0"8G#<O_P>^_.'LQU?/_A]02P,$%     @ J*#H7)SHTP9O P  I@P  !$
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M5@JEQ"6<"<55(;B$+YV]?\"Y*A+X("5,/,R2D1;--9;)2NJM+7-;++#B+U\
M4+24S16);*IQY,.PBL+MU,A$FSDKG6%N62,CIIBXT(@B&D!_C-O"4!H\Q?;
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MMVK%,@1/\(,Q$B=QK VH_)]+RLFPV3A8!3H=A3I+8D^@_PA4BN+BG^N_+#;
M5((KCK6.:<V&!?TG>$%$?ZPWK^1$W/,G@5].?P[86^S8H'\(0T/^L61+P)LR
M("280KBP8QNH0]W-!2+FZ9N"*WDMQ1WE4</WME4:SP'X*F,VZA_%HJ%OU6V)
M_^S=G4:GJ(8[!*U8J9N$!GX0Q^%:J"1D?]%E\QL]=H7G, IV4[9!V(I$&P.+
M:DM#D%4"70KSYDU[-NH&P-F+YX-0QJ D81/@MW.Z>@S*UKC8/>;U$-2.#A*X
MZ?_S1AF'4_P^MQZ <FS6#T3S9"*[G@O>\*;A;EY'0%8:$/;C/F#:M9#@3,4A
M5<>Z>=).OV5(FS3M!^H?DB8)X6.Q6*QX?E-&N=):D=P1LO561$V0#[PU@D@$
MYQ5@NX0WQ2TV7D:Y:?=^.-\(1B.:4#[[H%?<DH;,E65;9D<@UY@051$^"%>I
M(?'[( ^%OC>\;;5<)K=1WW[87DMBYH-H+-+'P<Q7!.35[:W[PJ%.H2.,'4R)
M?9$^6.]31<);EX%R'<@*05K)&_2V392!?Z(35/0OE%H1Z3\ %IWG,0;5!NW#
ML!./.!(5VFT-1E:NU?EHR5'ME#2RY;F\(=%*KZ<VP\/IA";,^1[';EY72YLJ
M \)^W&M98]7"6M3DXJ#5(97W7].TTN_6BJ9!TWZ@3F1HOFU[LUE,A?,2_%%2
M1XC:6Q>6@SYP6H20R,R5(9/VIK*%1LM(NG:+<]T\6T=S[98T>:+;GMOQ]=-J
M1%3'8%Q'=_6PKZ5%!9PGNMOKVWI-=6P>X_.]LP61,STUOTIQG\SU8F09\H;?
M9JR0Z/03OGI;8F^H_V=\-;)(K.<?C!6%(*L$>2FDS_A:M&'YD,_52WG'I=XR
MOW<BWT6SW[Z@]_P'4$L#!!0    ( *B@Z%QKX<KAN 0  (0J   5    ;6-R
M8BTR,#(V,#<P.%]P<F4N>&ULU9I=C^(V%(;O5]K_X*8WK=00 O.)AEU19F:%
M.A\(V+;JS<HD![#JV)$=!OCW/0YX12#,PG1;Q7,Q@./W^#WG<4QB<O-QF7#R
M DHS*=I>6*M[!$0D8R:F;6^N?:HCQCRB,RIBRJ6 MK<"[7W\\/[=S0^^3V[O
M>T_$)[,L2W4K"!:+12V>,*$EGV<84M<BF03$]VW_[N@S^7T]7(L,@ /50!H7
M89W\.F<\;C7JC8LZ?JR%VR(%U$0C,<V@12Z#J\#T(V&]==9H-<](_Y'<49V!
M$F3$$MB6RG2EV'26D9^BGTFNNI5" .>P(O=,4!$QRLG0^OV%]$14(QW.R<#(
M-)K4H%X@KFVB<B;^;IE_8V.=O']'\ ^K*'3>VO9,+3:E6(X5KTDU1;OU9F!%
MWK9FN2=:-'-)>'U]'>1'B_TU*^N- X3!GX\/PV@&"?61 !*+=H9"-W'V5;UM
M[CQ8'[3]-6OI/-*#C/+2'Y$6.=C#?/)M-]\T^6'#;X:UI8Z]#V;(=565Y#"
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M/[D^8OZ9IP&QY1]02P$"% ,4    " "HH.A<81?"2O44  ""G   #@
M        @ $     9#$P,#<S,V0X:RYH=&U02P$"% ,4    " "HH.A<EMI+
M_"!/  #U;@$ $0              @ $A%0  9#$P,#<S,V1E>#$P,2YH=&U0
M2P$"% ,4    " "HH.A<G.C3!F\#  "F#   $0              @ %P9
M;6-R8BTR,#(V,#<P."YX<V102P$"% ,4    " "HH.A<)-J2L5P&  "\0P
M%0              @ $.:   ;6-R8BTR,#(V,#<P.%]L86(N>&UL4$L! A0#
M%     @ J*#H7&OARN&X!   A"H  !4              ( !G6X  &UC<F(M
F,C R-C W,#A?<')E+GAM;%!+!08     !0 % $ !  "(<P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d100733d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mcrb-20260708.xsd" xlink:type="simple"/>
    <context id="duration_2026-07-08_to_2026-07-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001609809</identifier>
        </entity>
        <period>
            <startDate>2026-07-08</startDate>
            <endDate>2026-07-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-434">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-07-08_to_2026-07-08"
      id="Hidden_dei_EntityCentralIndexKey">0001609809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-445">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-446">2026-07-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-447">SERES THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-448">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-449">001-37465</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-450">27-4326290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-451">101 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-452">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-453">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-454">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-455">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-456">945-9626</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-457">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-458">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-459">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-460">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-461">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-462">MCRB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-463">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-07-08_to_2026-07-08" id="ixv-464">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
